Skip to main content
SpringerLink
Log in

Cancer Immunotherapy: Friend or Foe of Mental Health?

  • Chapter
  • First Online:
Cancer Genetics and Psychotherapy

  • 1006 Accesses

Abstract

Cancer morbidity with mental health problems is of utmost importance due to its considerable impact on mortality. Clinical trials demonstrate that immunotherapy could achieve clinical benefit in patients with cancer. However immunotherapy , like other treatments, has its potential side-effects such as autoimmunity, inflammatory responses, and immunosuppressive conditions-related side effects. As such evidence indicates that cancer immunotherapy might alter the patients’ mental health status, particularly depressive symptomatology, fatigue, anorexia, anxiety , and life quality, according to the immunotherapy-related factors, e.g. type, dosage, and regimen. The present chapter corroborates a number of conflicts concerning the possible link between cancer immunotherapy and mental health.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 219.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 279.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 379.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Abbreviations

APA:

American Psychiatric Association

CIK:

Cytokine-induced killer

CTLs:

Cytotoxic T lymphocytes

DSM:

Diagnostic and Statistical Manual

IFN-γ:

Interferon gamma

IL-2:

Interleukin 2

MADRS:

Montgomery-Asberg Depression Scale

MDD:

Major depressive disorder

NCS-R:

National Comorbidity Survey Replication

PSK:

Polysaccharide K

References

  • Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ et al (1993) The European ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365–376

    Article  CAS  PubMed  Google Scholar 

  • Aass N, Fosså SD, Dahl AA, Aloe TJ (1997) Prevalence of anxiety and depression in cancer patients seen at the Norwegian Radium Hospital. Eur j cancer 33:1597–1604

    Google Scholar 

  • Aguilar LK, Shirley LA, Chung VM, Marsh CL, Walker J, Coyle W et al (2015) Gene-mediated cytotoxic immunotherapy as adjuvant to surgery or chemoradiation for pancreatic adenocarcinoma. Cancer Immunol Immunother 64:727–736

    Article  CAS  PubMed  Google Scholar 

  • Amato MP, Ponziani G, Rossi F, Liedl CL, Stefanile C, Rossi L (2001) Quality of life in multiple sclerosis: the impact of depression, fatigue and disability. Multiple Sclerosis 7:340–344

    Article  CAS  PubMed  Google Scholar 

  • American Psychiatric A (2013) Diagnostic and statistical manual of mental disorders (DSM-5®). American Psychiatric Pub

    Google Scholar 

  • Arcelus J, Mitchell AJ, Wales J, Nielsen S (2011) Mortality rates in patients with anorexia nervosa and other eating disorders: a meta-analysis of 36 studies. Arch Gen Psychiatry 68:724–731

    Article  PubMed  Google Scholar 

  • Atzpodien J, Kuchler T, Wandert T, Reitz M (2003) Rapid deterioration in quality of life during interleukin-2- and alpha-interferon-based home therapy of renal cell carcinoma is associated with a good outcome. Br J Cancer 89:50–54

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Baer MR, GEORGE SL, Caligiuri MA, Sanford BL, Bothun SM, MRóZEK K et al (2008) Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: cancer and leukemia group B study 9720. J Clin Oncol 26:4934–4939

    Google Scholar 

  • Bakshi R (2003) Fatigue associated with multiple sclerosis: diagnosis, impact and management. Multiple Sclerosis 9:219–227

    Article  PubMed  Google Scholar 

  • Baxter AJ, Scott KM, Vos T, Whiteford HA (2013) Global prevalence of anxiety disorders: a systematic review and meta-regression. Psychol Med 43:897–910

    Article  CAS  PubMed  Google Scholar 

  • Beer TM, Bernstein GT, Corman JM, Glode LM, Hall SJ, Poll WL et al (2011) Randomized trial of autologous cellular immunotherapy with sipuleucel-T in androgen-dependent prostate cancer. Clin Cancer Res 17:4558–4567

    Article  CAS  PubMed  Google Scholar 

  • Bergmann L, Fenchel K, Weidmann E, Enzinger HM, Jahn B, Jonas D et al (1993) Daily alternating administration of high-dose alpha-2b-interferon and interleukin-2 bolus infusion in metastatic renal cell cancer. A phase II study. Cancer 72:1733–1742

    Article  CAS  PubMed  Google Scholar 

  • Bohle A, Balck F, von Weitersheim J, Jocham D (1996) The quality of life during intravesical bacillus Calmette-Guerin therapy. J Urol 155:1221–1226

    Article  CAS  PubMed  Google Scholar 

  • Brintzenhofe-Szoc KM, Levin TT, Li Y, Kissane DW, Zabora JR (2009) Mixed anxiety/depression symptoms in a large cancer cohort: prevalence by cancer type. Psychosomatics 50:383–391

    Article  PubMed  Google Scholar 

  • Brown LF, Kroenke K (2009) Cancer-related fatigue and its associations with depression and anxiety: a systematic review. Psychosomatics 50:440–447

    Article  PubMed  PubMed Central  Google Scholar 

  • Burch PA, Breen JK, Buckner JC, Gastineau DA, Kaur JA, Laus RL et al (2000) Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer. Clin Cancer Res 6:2175–2182

    CAS  PubMed  Google Scholar 

  • Capuron L, Ravaud A, Dantzer R (2000) Early depressive symptoms in cancer patients receiving interleukin 2 and/or interferon alfa-2b therapy. J Clin Oncol 18:2143–2151

    Article  CAS  PubMed  Google Scholar 

  • Capuron L, Ravaud A, Gualde N, Bosmans E, Dantzer R, Maes M et al (2001) Association between immune activation and early depressive symptoms in cancer patients treated with interleukin-2-based therapy. Psychoneuroendocrinology 26:797–808

    Article  CAS  PubMed  Google Scholar 

  • Capuron L, Ravaud A, Miller AH, Dantzer R (2004) Baseline mood and psychosocial characteristics of patients developing depressive symptoms during interleukin-2 and/or interferon-alpha cancer therapy. Brain Behav Immun 18:205–213

    Article  CAS  PubMed  Google Scholar 

  • Capuron L, Ravaud A, Neveu PJ, Miller AH, Maes M, Dantzer R (2002) Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy. Molecular psychiatry 7:468–473

    Article  CAS  PubMed  Google Scholar 

  • Caraceni A, Gangeri L, Martini C, Belli F, Brunelli C, Baldini M et al (1998) Neurotoxicity of interferon-alpha in melanoma therapy: results from a randomized controlled trial. Cancer 83:482–489

    Article  CAS  PubMed  Google Scholar 

  • Chapman DP, Perry GS, Strine TW (2005) The vital link between chronic disease and depressive disorders. Prev Chronic Dis 2:A14

    PubMed  Google Scholar 

  • Chen R, Deng X, Wu H, Peng P, Wen B, Li F et al (2014) Combined immunotherapy with dendritic cells and cytokine-induced killer cells for malignant tumors: a systematic review and meta-analysis. Int Immunopharmacol 22:451–464

    Article  CAS  PubMed  Google Scholar 

  • Chiarion-Sileni V, del Bianco P, de Salvo GL, Re GL, Romanini A, Labianca R et al (2003) Quality of life evaluation in a randomised trial of chemotherapy versus bio-chemotherapy in advanced melanoma patients. Eur J Cancer 39:1577–1585

    Article  CAS  PubMed  Google Scholar 

  • Chiocca EA, Aguilar LK, Bell SD, Kaur B, Hardcastle J, Cavaliere R et al (2011) Phase IB study of gene-mediated cytotoxic immunotherapy adjuvant to up-front surgery and intensive timing radiation for malignant glioma. J Clin Oncol 29:3611–3619

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Chren M-M, Lasek RJ, Quinn LM, Mostow EN, Zyzanski SJ (1997) Skindex, a quality-of-life measure for patients with skin disease: reliability, validity, and responsiveness. J Invest Dermatol 107:707–713

    Article  Google Scholar 

  • Chung MJ, Park JY, Bang S, Park SW, Song SY (2014) Phase II clinical trial of ex vivo-expanded cytokine-induced killer cells therapy in advanced pancreatic cancer. Cancer Immunol Immunother 63:939–946

    Article  CAS  PubMed  Google Scholar 

  • Coates A, Gebski V, Bishop JF, Jeal PN, Woods RL, Snyder R et al (1987) Improving the quality of life during chemotherapy for advanced breast cancer. N Engl J Med 317:1490–1495

    Article  CAS  PubMed  Google Scholar 

  • Cohen L, Parker PA, Sterner J, de Moor C (2002) Quality of life in patients with malignant melanoma participating in a phase I trial of an autologous tumour-derived vaccine. Melanoma Res 12:505–511

    Article  CAS  PubMed  Google Scholar 

  • Cui J, Li L, Wang C, Jin H, Yao C, Wang Y et al (2015) Combined cellular immunotherapy and chemotherapy improves clinical outcome in patients with gastric carcinoma. Cytotherapy 17:979–988

    Article  CAS  PubMed  Google Scholar 

  • Curreli L, Lampis B, Santona MC, Mantovani G (1996) Chemo-immunotherapy for advanced-stage malignancies and its impact on quality of life: multidimensional evaluation in ten cancer patients. Support Care Cancer 4:462–464

    Article  CAS  PubMed  Google Scholar 

  • Curt GA (2000) Impact of fatigue on quality of life in oncology patients. Semin Hematol 37(Supplement 6):14–17

    Article  CAS  PubMed  Google Scholar 

  • Curt GA, Breitbart W, Cella D, Groopman JE, Horning SJ, Itri LM et al (2000) Impact of cancer-related fatigue on the lives of patients: new findings from the fatigue coalition. Oncologist 5:353–360

    Article  CAS  PubMed  Google Scholar 

  • Derogatis LR, Morrow GR, Fetting J, Penman D, Piasetsky S, Schmale AM et al (1983) The prevalence of psychiatric disorders among cancer patients. JAMA 249:751–757

    Article  CAS  PubMed  Google Scholar 

  • Di L, Zhu Y, Jia J, Yu J, Song G, Zhang J et al (2012) Clinical safety of induced CTL infusion through recombinant adeno-associated virus-transfected dendritic cell vaccination in Chinese cancer patients. Clin Transl Oncol 14:675–681

    Article  CAS  PubMed  Google Scholar 

  • Dijkgraaf EM, Santegoets SJ, Reyners AK, Goedemans R, Nijman HW, van Poelgeest MI et al (2015) A phase 1/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum-resistant ovarian cancer. Oncotarget 6:32228–32243

    Article  PubMed  PubMed Central  Google Scholar 

  • Evans WJ, Morley JE, Argiles J, Bales C, Baracos V, Guttridge D et al (2008) Cachexia: a new definition. Clin Nutr 27:793–799

    Article  CAS  PubMed  Google Scholar 

  • Fava M, Rankin MA, Wright EC, Alpert JE, Nierenberg AA, Pava J et al (2000) Anxiety disorders in major depression. Compr Psychiatry 41:97–102

    Article  CAS  PubMed  Google Scholar 

  • Felce D, Perry J (1995) Quality of life: its definition and measurement. Res Dev Disabil 16:51–74

    Article  CAS  PubMed  Google Scholar 

  • Ferrell BR, Dow KH, Leigh S, Ly J, Gulasekaram P (1995) Quality of life in long-term cancer survivors. Oncol Nurs Forum 22(6):915–922

    Google Scholar 

  • Fisk JD, Pontefract A, Ritvo PG, Archibald CJ, Murray TJ (1994) The impact of fatigue on patients with multiple sclerosis. Can J Neurol Sci/J Can des Sci Neurologiques 21:9–14

    Article  CAS  Google Scholar 

  • Franco-Molina MA, Mendoza-Gamboa E, Zapata-Benavides P, Vera-Garcia ME, Castillo-Tello P, Garcia de la Fuente A et al (2008) IMMUNEPOTENT CRP (bovine dialyzable leukocyte extract) adjuvant immunotherapy: a phase I study in non-small cell lung cancer patients. Cytotherapy 10:490–496

    Google Scholar 

  • Freeman MP, Freeman SA, McElroy SL (2002) The comorbidity of bipolar and anxiety disorders: prevalence, psychobiology, and treatment issues. J Affect Disord 68:1–23

    Article  PubMed  Google Scholar 

  • Fritz H, Kennedy DA, Ishii M, Fergusson D, Fernandes R, Cooley K and Seely D (2015) Polysaccharide K and Coriolus versicolor extracts for lung cancer: a systematic review. Integr Cancer Ther 14(3):201–211

    Google Scholar 

  • Garcia JA, Elson P, Tyler A, Triozzi P, Dreicer R (2014) Sargramostim (GM-CSF) and lenalidomide in castration-resistant prostate cancer (CRPC): results from a phase I-II clinical trial. Elsevier, Amstredam, p 33–e11

    Google Scholar 

  • Gardner T, Elzey B, Hahn NM (2012) Sipuleucel-T (Provenge) autologous vaccine approved for treatment of men with asymptomatic or minimally symptomatic castrate-resistant metastatic prostate cancer. Human vaccines & immunotherapeutics 8:534–539

    Article  CAS  Google Scholar 

  • Giese-Davis J, Collie K, Rancourt KMS, Neri E, Kraemer HC, Spiegel D (2011) Decrease in depression symptoms is associated with longer survival in patients with metastatic breast cancer: a secondary analysis. J Clin Oncol 29:413–420

    Article  PubMed  Google Scholar 

  • Glimelius B, Hoffman K, Sjöden P-O, Jacobsson G, Sellström H, Enander L-K et al (1996) Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 7:593–600

    Google Scholar 

  • Goldblatt J, Taylor PJS, Lipman T, Prince MI, Baragiotta A, Bassendine MF et al (2002) The true impact of fatigue in primary biliary cirrhosis: a population study. Gastroenterology 122:1235–1241

    Article  PubMed  Google Scholar 

  • Grant BF, Stinson FS, Dawson DA, Chou SP, Dufour MC, Compton W et al (2004) Prevalence and co-occurrence of substance use disorders and independentmood and anxiety disorders: results from the national epidemiologic survey on alcohol and relatedconditions. Arch Gen Psychiatry 61:807–816

    Article  PubMed  Google Scholar 

  • Guinan P, Toronchi E, Shaw M, Crispin R, Sharifi R (1982) Bacillus calmette-guerin (BCG) adjuvant therapy in stage D prostate cancer. Urology 20:401–403

    Article  CAS  PubMed  Google Scholar 

  • Guo W, Liu L, Wu D (2014) Dendritic cell-cytokine induced killer cell immunotherapy combined with transcatheter arterial chemoembolization for hepatocellular carcinoma: safety and efficacy. Nan fang yi ke da xue xue bao = J South Med Univ 34:674–678

    Google Scholar 

  • Hales RK, Banchereau J, Ribas A, Tarhini AA, Weber JS, Fox BA et al (2010) Assessing oncologic benefit in clinical trials of immunotherapy agents. Ann Oncol 21:1944–1951

    Article  CAS  PubMed  Google Scholar 

  • Heinzer H, Mir TS, Huland E, Huland H (1999) Subjective and objective prospective, long-term analysis of quality of life during inhaled interleukin-2 immunotherapy. J Clin Oncol 17:3612–3620

    Article  CAS  PubMed  Google Scholar 

  • Hettema JM, Neale MC, Kendler KS (2001) A review and meta-analysis of the genetic epidemiology of anxiety disorders. Am J Psychiatry 158(10):1568–1578

    Google Scholar 

  • Hirschfeld R (1999) Personality disorders and depression: comorbidity. Depress Anxiety 10:142–146

    Article  CAS  PubMed  Google Scholar 

  • Hoek HW, van Hoeken D (2003) Review of the prevalence and incidence of eating disorders. Int J Eat Disord 34:383–396

    Article  PubMed  Google Scholar 

  • Hofman M, Ryan JL, Figueroa-Moseley CD, Jean-Pierre P, Morrow GR (2007) Cancer-related fatigue: the scale of the problem. Oncologist 12:4–10

    Article  PubMed  Google Scholar 

  • Hontscha C, Borck Y, Zhou H, Messmer D, Schmidt-Wolf IGH (2010) Clinical trials on CIK cells: first report of the international registry on CIK cells (IRCC). J Cancer Res Clin Oncol 137:305–310

    Article  PubMed  Google Scholar 

  • Hsueh EC, Nathanson L, Foshag LJ, Essner R, Nizze JA, Stern SL et al (1999) Active specific immunotherapy with polyvalent melanoma cell vaccine for patients with in-transit melanoma metastases. Cancer 85:2160–2169

    Article  CAS  PubMed  Google Scholar 

  • Huet P-M, Deslauriers J, Tran A, Faucher C, Charbonneau J (2000) Impact of fatigue on the quality of life of patients with primary biliary cirrhosis. Am J Gastroenterol 95:760–767

    Article  CAS  PubMed  Google Scholar 

  • Ibrahim AK, Kelly SJ, Adams CE, Glazebrook C (2013) A systematic review of studies of depression prevalence in university students. J Psychiatr Res 47:391–400

    Article  PubMed  Google Scholar 

  • Ingles JL, Eskes GA, Phillips SJ (1999) Fatigue after stroke. Arch Phys Med Rehabil 80:173–178

    Article  CAS  PubMed  Google Scholar 

  • Inui A (2002) Cancer anorexia-cachexia syndrome: current issues in research and management. CA Cancer J Clin 52:72–91

    Article  PubMed  Google Scholar 

  • Iwai K, Soejima K, Kudoh S, Umezato Y, Kaneko T, Yoshimori K et al (2012) Extended survival observed in adoptive activated T lymphocyte immunotherapy for advanced lung cancer: results of a multicenter historical cohort study. Cancer Immunol Immunother 61:1781–1790

    Article  PubMed  PubMed Central  Google Scholar 

  • Jacobson AM, de Groot M, Samson JA (1994) The evaluation of two measures of quality of life in patients with type I and type II diabetes. Diabetes Care 17:267–274

    Article  CAS  PubMed  Google Scholar 

  • Jansen RL, Slingerland R, Goey SH, Franks CR, Bolhuis RL, Stoter G (1992a) Interleukin-2 and interferon-alpha in the treatment of patients with advanced non-small-cell lung cancer. J Immunother 1991(12):70–73

    Article  Google Scholar 

  • Jansen RLH, Slingerland R, Goey SH, Franks CR, Bolhuis RLH, Stoter G (1992b) Interleukin-2 and Interferon-[alpha] in the treatment of patients with advanced non-small-cell lung cancer. J Immunother 12:70–73

    Article  CAS  PubMed  Google Scholar 

  • Kadan-Lottick NS, Vanderwerker LC, Block SD, Zhang B, Prigerson HG (2005) Psychiatric disorders and mental health service use in patients with advanced cancer. Cancer 104:2872–2881

    Article  PubMed  PubMed Central  Google Scholar 

  • Katon W, Lin EHB, Kroenke K (2007) The association of depression and anxiety with medical symptom burden in patients with chronic medical illness. Gen Hosp Psychiatry 29:147–155

    Article  PubMed  Google Scholar 

  • Kerst JM, Bex A, Mallo H, Dewit L, Haanen J, Boogerd W et al (2005) Prolonged low dose IL-2 and thalidomide in progressive metastatic renal cell carcinoma with concurrent radiotherapy to bone and/or soft tissue metastasis: a phase II study. Cancer Immunol Immunother 54:926–931

    Article  CAS  PubMed  Google Scholar 

  • Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR et al (2003) The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 289:3095–3105

    Article  PubMed  Google Scholar 

  • Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE (2005) Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 62:593–602

    Article  PubMed  Google Scholar 

  • Kessler RC, Nelson CB, McGonagle KA, Liu J,Swartz M, Blazer DG (1996) Comorbidity of Dsm-iii-r major depressive disorder in the general population: results from the US National Comorbidity Survey. Br J Psychiatry 168(30S):17–30

    Google Scholar 

  • Kimura H, Iizasa T, Ishikawa A, Shingyouji M, Yoshino M, Kimura M et al (2008) Prospective phase II study of post-surgical adjuvant chemo-immunotherapy using autologous dendritic cells and activated killer cells from tissue culture of tumor-draining lymph nodes in primary lung cancer patients. Anticancer Res 28:1229–1238

    CAS  PubMed  Google Scholar 

  • Kimura Y, Iijima S, Kato T, Tsujie M, Naoi Y, Hayashi T et al (2003) Usefulness of TS-1 and lentinan combination immunochemotherapy in advanced or recurrent gastric cancer–pilot study aiming at a randomized trial. Gan To Kagaku Ryoho 30:1125–1130

    PubMed  Google Scholar 

  • Kobold S, Duewell P, Schnurr M, Subklewe M, Rothenfusser S, Endres S (2015) Immunotherapy in Tumors. Dtsch Arztebl Int 112:809–815

    PubMed  PubMed Central  Google Scholar 

  • Krebber AMH, Buffart LM, Kleijn G, Riepma IC, Bree R, Leemans CR et al (2014) Prevalence of depression in cancer patients: a meta-analysis of diagnostic interviews and self-report instruments. Psycho-Oncology 23:121–130

    Article  CAS  PubMed  Google Scholar 

  • Lammers RJM, Witjes WPJ, Janzing-Pastors MHD, Caris CTM, Witjes JA (2012) Intracutaneous and intravesical immunotherapy with keyhole limpet hemocyanin compared with intravesical mitomycin in patients with non–muscle-invasive bladder cancer: results from a prospective randomized phase III trial. J Clin Oncol 30:2273–2279

    Article  CAS  PubMed  Google Scholar 

  • Lara PN, Quinn DI, Margolin K, Meyers FJ, Longmate J, Frankel P et al (2003) SU5416 plus interferon α in advanced renal cell carcinoma a phase II California cancer consortium study with biological and imaging correlates of angiogenesis inhibition. Clin Cancer Res 9:4772–4781

    CAS  PubMed  Google Scholar 

  • Lehtinen V, Joukamaa M (1994) Epidemiology of depression: Prevalence, risk factors and treatment situation. Acta Psychiatr Scand 89:7–10

    Article  Google Scholar 

  • Lepine J-P (2002) The epidemiology of anxiety disorders: prevalence and societal costs. J Clin Psychiatry 14(Suppl 63):4–8

    Google Scholar 

  • Linden W, Vodermaier A, Mackenzie R, Greig D (2012) Anxiety and depression after cancer diagnosis: prevalence rates by cancer type, gender, and age. J Affect Disord 141:343–351

    Article  PubMed  Google Scholar 

  • Lissoni P, Barni S, Rovelli F, Pittalis S, Ardizzoia A, Tancini G et al (1993) In vivo biological results of the association between interleukin-2 and interleukin-3 in the immunotherapy of cancer. Eur J Cancer 29:1127–1132

    Article  Google Scholar 

  • Lissoni P, Brivio F, Barni S, Tancini G, Cattaneo G, Archili C et al (1990) Neuroimmunotherapy of human cancer with interleukin-2 and the neurohormone melatonin: its efficacy in preventing hypotension. Anticancer Res 10:1759–1761

    CAS  PubMed  Google Scholar 

  • Littlewood TJ, Bajetta E, Nortier JWR, Vercammen E, Rapoport B, Epoetin Alfa Study Group (2001) Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 19:2865–2874

    Google Scholar 

  • Litwin MS, Fine JT, Dorey F, Figlin RA, Belldegrun AS (1997) Health related quality of life outcomes in patients treated for metastatic kidney cancer: a pilot study. J Urol 157:1608–1612

    Article  CAS  PubMed  Google Scholar 

  • Loge JH, Ekeberg Ø, Kaasa S (1998) Fatigue in the general Norwegian population: normative data and associations. J Psychosom Res 45:53–65

    Article  CAS  PubMed  Google Scholar 

  • Lu W, Cui Y, Chen X, Zheng Y, Gu K, Cai H et al (2009) Changes in quality of life among breast cancer patients three years post-diagnosis. Breast Cancer Res Treat 114:357–369

    Article  PubMed  Google Scholar 

  • Lueboonthavatchai P (2007) Prevalence and psychosocial factors of anxiety and depression in breast cancer patients. J Med Assoc Thai= Chotmaihet Thangphaet 90:2164–2174

    PubMed  Google Scholar 

  • Lummen G, Schenck M, Borgermann C, EIsenhardt A, Vom Dorp F, Sperling H et al (2004) Inhaled immunotherapy for pulmonary metastases of renal cell cancer. Urologe A 43:457–61

    Google Scholar 

  • Mack D, Frick J (1996) Quality of life in patients undergoing bacille Calmette-Guerin therapy for superficial bladder cancer. Br J Urol 78:369–371

    Article  CAS  PubMed  Google Scholar 

  • Maes M, Capuron L, Ravaud A, Gualde N, Bosmans E, Egyed B et al (2001) Lowered serum dipeptidyl peptidase IV activity is associated with depressive symptoms and cytokine production in cancer patients receiving interleukin-2-based immunotherapy. Neuropsychopharmacology 24:130–140

    Article  CAS  PubMed  Google Scholar 

  • Maroto JP, Muro XG, Mellado B, Perez-Gracia JL, Andres R, Cruz J et al (2013) Phase II trial of sequential subcutaneous interleukin-2 plus interferon alpha followed by sorafenib in renal cell carcinoma (RCC). Clin Transl Oncol 15:698–704

    Article  CAS  PubMed  Google Scholar 

  • Martinez-Martin P, Catalan MJ, Benito-Leon J, Moreno AO, Zamarbide I, Cubo E et al (2006) Impact of fatigue in Parkinson’s disease: the fatigue impact scale for daily use (D-FIS). Qual Life Res 15:597–606

    Article  PubMed  Google Scholar 

  • McLean CP, Asnaani A, Litz BT, Hofmann SG (2011) Gender differences in anxiety disorders: prevalence, course of illness, comorbidity and burden of illness. J Psychiatr Res 45:1027–1035

    Article  PubMed  PubMed Central  Google Scholar 

  • Mitchell AJ, Ferguson DW, Gill J, Paul J, Symonds P (2013) Depression and anxiety in long-term cancer survivors compared with spouses and healthy controls: a systematic review and meta-analysis. Lancet Oncol 14:721–732

    Article  PubMed  Google Scholar 

  • Montgomery SA, Asberg M (1979) A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382–389

    Article  CAS  PubMed  Google Scholar 

  • Musante GJ, Costanzo PR, Friedman KE (1998) The comorbidity of depression and eating dysregulation processes in a diet-seeking obese population: a matter of gender specificity. Int J Eat Disord 23:65–75

    Article  CAS  PubMed  Google Scholar 

  • Nagao A, Takei Y, Ogawa Y, Shimada M, Tanigawa K, Suzuki S (2012) Examination of the quality of life in the cancer patients under immunotherapy. Gan To Kagaku Ryoho 39:1785–1787

    PubMed  Google Scholar 

  • Nencioni A, Grunebach F, Schmidt SM, Muller MR, Boy D, Patrone F et al (2008) The use of dendritic cells in cancer immunotherapy. Crit Rev Oncol Hematol 65:191–199

    Article  PubMed  Google Scholar 

  • Neri B, Doni L, Gemelli MT, Fulignati C, Turrini M, di Cello V et al (2002) Phase II trial of weekly intravenous gemcitabine administration with interferon and interleukin-2 immunotherapy for metastatic renal cell cancer. J urol 168:956–958

    Article  CAS  PubMed  Google Scholar 

  • Nimura H, Mitsumori N, Tsukagoshi S, Nakajima M, Atomi Y, Suzuki S et al (2003) Pilot study of TS-1 combined with lentinan in patients with unresectable or recurrent advanced gastric cancer. Gan to kagaku ryoho Cancer Chemother 30:1289–1296

    Google Scholar 

  • Niu J, Ren Y, Zhang T, Yang X, Zhu W, Zhu H et al (2014) Retrospective comparative study of the effects of dendritic cell vaccine and cytokine-induced killer cell immunotherapy with that of chemotherapy alone and in combination for colorectal cancer. BioMed Res Int

    Google Scholar 

  • Ochiai T, Suzuki T, Gunji Y, Okuyama K, Koide Y, Isono K (1990) Immunotherapy and quality of life. Gan To Kagaku Ryoho 17:902–906

    CAS  PubMed  Google Scholar 

  • Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12:252–264

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Patrick DL, Deyo RA, Atlas SJ, Singer DE, Chapin A, Keller RB (1995) Assessing health-related quality of life in patients with sciatica. Spine 20:1899–1908

    Article  CAS  PubMed  Google Scholar 

  • Pawlikowska T, Chalder T, Hirsch SR, Wallace P, Wright DJM, Wessely SC (1994) Population based study of fatigue and psychological distress. BMJ 308:763–766

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Pinquart M, Duberstein PR (2010) Depression and cancer mortality: a meta-analysis. Psychol Med 40:1797–1810

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Pizza G, De Vinci C, Lo Conte G, Maver P, Dragoni E, Aiello E et al (2001) Immunotherapy of metastatic kidney cancer. Int J Cancer 94:109–120

    Google Scholar 

  • Pizzi C, Caraglia M, Cianciulli M, Fabbrocini A, Libroia A, Matano E et al (2002) Low-dose recombinant IL-2 induces psychological changes: monitoring by Minnesota Multiphasic Personality Inventory (MMPI). Anticancer Res 22:727–732

    CAS  PubMed  Google Scholar 

  • Plata-Salamán CR (1996) Anorexia during acute and chronic disease. Nutrition 12:69–78

    Google Scholar 

  • Quoix E, Lena H, Losonczy G, Forget F, Chouaid C, Papai Z et al (2015) TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial. Lancet Oncol 17(2):212–223

    Google Scholar 

  • Quoix E, Ramlau R, Westeel V, Papai Z, Madroszyk A, Riviere A et al (2011) Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial. Lancet Oncol 12:1125–1133

    Article  CAS  PubMed  Google Scholar 

  • Rector NA, Szacun-Shimizu K, Leybman M (2007) Anxiety sensitivity within the anxiety disorders: Disorder-specific sensitivities and depression comorbidity. Behav Res Ther 45:1967–1975

    Article  PubMed  Google Scholar 

  • Regier DA, Rae DS, Narrow WE, Kaelber CT, Schatzberg AF (1998) Prevalence of anxiety disorders and their comorbidity with mood and addictive disorders. Br J Psychiatry

    Google Scholar 

  • Ricci JA, Chee E, Lorandeau AL, Berger J (2007) Fatigue in the US workforce: prevalence and implications for lost productive work time. J Occup Environ Med 49:1–10

    Article  PubMed  Google Scholar 

  • Riolo SA, Nguyen TA, Greden JF, King CA (2005) Prevalence of depression by race/ethnicity: findings from the National Health and Nutrition Examination Survey III. Am J Public Health 95:998–1000

    Article  PubMed  PubMed Central  Google Scholar 

  • Roy-Byrne PP, Stang P, Wittchen H-U, Ustun B, Walters E, Kessler RC (2000) Lifetime panic-depression comorbidity in the National Comorbidity Survey. Br J Psychiatry 176:229–235

    Article  CAS  PubMed  Google Scholar 

  • Ryan CJ, Weinberg V, Rosenberg J, Fong L, Lin A, Kim J et al (2007) Phase II study of ketoconazole plus granulocyte-macrophage colony-stimulating factor for prostate cancer: effect of extent of disease on outcome. J Urol 178:2372–2377

    Article  CAS  PubMed  Google Scholar 

  • Saghazadeh A, Saghazadeh M, Rezaei N (2015) Immunology of cutaneous tumors and immunotherapy for melanoma. Springer, Cancer Immunology

    Book  Google Scholar 

  • Sareen J, Jacobi F, Cox BJ, Belik S-L, Clara I, Stein MB (2006) Disability and poor quality of life associated with comorbid anxiety disorders and physical conditions. Arch Intern Med 166:2109–2116

    Article  PubMed  Google Scholar 

  • Schenck M, Borgermann C, Jager T, Vom Dorp F, Sperling H, Rubben H et al (2007) Immunotherapy of metastatic renal cell carcinoma with interleukin-2, interferon-alpha2a and erythropoietin-beta. Urologe A 46:528–34

    Google Scholar 

  • Schmeel FC, Schmeel LC, Gast SM, Schmidt-Wolf IG (2014) Adoptive immunotherapy strategies with cytokine-induced killer (CIK) cells in the treatment of hematological malignancies. Int J Mol Sci 15:14632–14648

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Schmeel LC, Schmeel FC, Coch C, Schmidt-Wolf IGH (2015) Cytokine-induced killer (CIK) cells in cancer immunotherapy: report of the international registry on CIK cells (IRCC). J Cancer Res Clin Oncol 141:839–849

    Article  CAS  PubMed  Google Scholar 

  • Schuchter LM, Wohlganger J, Fishman EK, Macdermott ML, McGuire WP (1992) Sequential chemotherapy and immunotherapy for the treatment of metastatic melanoma. J Immunother 1991(12):272–276

    Article  Google Scholar 

  • Shen J, Barbera J, Shapiro CM (2006) Distinguishing sleepiness and fatigue: focus on definition and measurement. Sleep Med Rev 10:63–76

    Article  PubMed  Google Scholar 

  • Siegel RL, Miller KD, Jemal A (2015a) Cancer statistics, 2015. CA Cancer J Clin 65:5–29

    Article  PubMed  Google Scholar 

  • Siegel RL, Miller KD, Jemal A (2015b) Cancer statistics, 2016. CA Cancer J Clin, CA

    Google Scholar 

  • Small EJ, Sacks N, Nemunaitis J, Urba WJ, Dula E, Centeno AS et al (2007) Granulocyte macrophage colony-stimulating factor–secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer. Clin Cancer Res 13:3883–3891

    Article  CAS  PubMed  Google Scholar 

  • Spelten ER, Verbeek JHAM, Uitterhoeve ALJ, Ansink AC, van der Lelie J, de Reijke TM et al (2003) Cancer, fatigue and the return of patients to work—a prospective cohort study. Eur J Cancer 39:1562–1567

    Article  CAS  PubMed  Google Scholar 

  • Spitzer WO, Dobson AJ, Hall J, Chesterman E, Levi J, Shepherd R et al (1981) Measuring the quality of life of cancer patients: a concise QL-index for use by physicians. J Chronic Dis 34:585–597

    Article  CAS  PubMed  Google Scholar 

  • Stadler WM, Rybak ME, Vogelzang NJ (1995) A phase II study of subcutaneous recombinant human lnterleukjn-4 in metastatic renal cell carcinoma. Cancer 76:1629–1633

    Article  CAS  PubMed  Google Scholar 

  • Stanford JL, O’Brien MER, Grange JM (2008) Successful immunotherapy with Mycobacterium vaccae in the treatment of adenocarcinoma of the lung. Eur J Cancer 44:224–227

    Article  CAS  PubMed  Google Scholar 

  • Stark D, Kiely M, Smith A, Velikova G, House A, Selby P (2002) Anxiety disorders in cancer patients: their nature, associations, and relation to quality of life. J Clin Oncol 20:3137–3148

    Article  CAS  PubMed  Google Scholar 

  • Stone P, Hardy J, Broadley K, Kurowska A, A’Hern R (1999) Fatigue in advanced cancer: a prospective controlled cross-sectional study. Br J Cancer 79:1479

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Stone P, Richardson A, Ream E, Smith AG, Kerr DJ, Kearney N et al (2000) Cancer-related fatigue: inevitable, unimportant and untreatable? Results of a multi-centre patient survey. Ann Oncol 11:971–975

    Article  CAS  PubMed  Google Scholar 

  • Takyar S, Diaz J, Sehgal M, Sapunar F, Pandha H (2016) First-line therapy for treatment-naive patients with advanced/metastatic renal cell carcinoma: a systematic review of published randomized controlled trials. Anticancer Drugs

    Google Scholar 

  • Tan BHL, Fearon KCH (2008) Cachexia: prevalence and impact in medicine. Current Opin Clin Nutr Metab Care 11:400–407

    Article  Google Scholar 

  • Tanaka N, Gouchi A, Ohara T, Mannami T, Konaga E, Fuchimoto S et al (1994) Intratumoral injection of a streptococcal preparation, OK-432, before surgery for gastric cancer. A randomized trial. Cancer 74:3097–3103

    Article  CAS  PubMed  Google Scholar 

  • Tarhini AA, Cherian J, Moschos SJ, Tawbi HA, Shuai Y, Gooding WE et al (2012) Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma. J Clin Oncol 30:322–328

    Article  CAS  PubMed  Google Scholar 

  • van den Eertwegh AJM, Versluis J, van den Berg HP, Santegoets SJAM, van Moorselaar RJA, van der Sluis TM et al (2012) Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol 13:509–517

    Article  PubMed  CAS  Google Scholar 

  • van den Heuvel MM, Verheij M, Boshuizen R, Belderbos J, Dingemans A-MC, de Ruysscher D et al (2015) NHS-IL2 combined with radiotherapy: preclinical rationale and phase Ib trial results in metastatic non-small cell lung cancer following first-line chemotherapy. J Transl Med 13:e45

    Article  CAS  Google Scholar 

  • van Gool AR, Fekkes D, Kruit WH, Mulder PG, ten Hagen TL, Bannink M et al (2003) Serum amino acids, biopterin and neopterin during long-term immunotherapy with interferon-alpha in high-risk melanoma patients. Psychiatry Res 119:125–132

    Article  PubMed  CAS  Google Scholar 

  • van Gool AR, Verkerk R, Fekkes D, Sleijfer S, Bannink M, Kruit WH et al (2008) Plasma activity of prolyl endopeptidase in relation to psychopathology during immunotherapy with IFN-alpha in patients with renal cell carcinoma. J Interferon Cytokine Res 28:283–286

    Article  PubMed  CAS  Google Scholar 

  • Vanneman M, Dranoff G (2012) Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer 12:237–251

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Vickrey BG, Hays RD, Harooni R, Myers LW, Ellison GW (1995) A health-related quality of life measure for multiple sclerosis. Quality of Life Research 4:187–206

    Google Scholar 

  • Vinokur AD, Threatt BA, Vinokur-Kaplan D, Satariano WA (1990) The process of recovery from breast cancer for younger and older patients. Changes during the first year. Cancer 65:1242–1254

    Article  CAS  PubMed  Google Scholar 

  • Wagner LI, Cella D (2004) Fatigue and cancer: causes, prevalence and treatment approaches. Br J Cancer 91:822–828

    CAS  PubMed  PubMed Central  Google Scholar 

  • Wang Y, Xu Z, Zhou F, Sun Y, Chen J, Li L et al (2015) The combination of dendritic cells-cytotoxic T lymphocytes/cytokine-induced killer (DC-CTL/CIK) therapy exerts immune and clinical responses in patients with malignant tumors. Exp Hematol Oncol 4:1

    Article  Google Scholar 

  • Watson M, Greer S, Rowden L, Gorman C, Robertson B, Bliss JM et al (1991) Relationships between emotional control, adjustment to cancer and depression and anxiety in breast cancer patients. Psychol Med 21:51–57

    Article  CAS  PubMed  Google Scholar 

  • Weihrauch MR, Richly H, Von Bergwelt-Baildon MS, Becker HJ, Schmidt M, Hacker UT et al (2015) Phase I clinical study of the toll-like receptor 9 agonist MGN1703 in patients with metastatic solid tumours. Eur J Cancer 51:146–156

    Article  CAS  PubMed  Google Scholar 

  • Yano T, Ishida T, Yoshino I, Murata M, Yasumoto K, Kimura G et al (1991) A regimen of surgical adjuvant immunotherapy for cancer with interleukin 2 and lymphokine-activated killer cells. Biotherapy 3:245–251

    Article  CAS  PubMed  Google Scholar 

  • Zabora J, Brintzenhofeszoc K, Curbow B, Hooker C, Piantadosi S (2001) The prevalence of psychological distress by cancer site. Psycho-Oncology 10:19–28

    Article  CAS  PubMed  Google Scholar 

  • Zhang L, Zhu W, Li J, Yang X, Ren Y, Niu J et al (2016) Clinical outcome of immunotherapy with dendritic cell vaccine and cytokine-induced killer cell therapy in hepatobiliary and pancreatic cancer. Mol Clin Oncol 4:129–133

    Article  PubMed  Google Scholar 

  • Zhang Y, Xia L, Zhang Y, Wang Y, Lu X, Shi F et al (2015) Analysis of adverse events following the treatment of autologous cytokine-induced killer cells for adoptive immunotherapy in malignant tumour sufferers. Expert Opin Biol Ther 15:481–493

    Article  CAS  PubMed  Google Scholar 

  • Zhong R, Teng J, Han B, Zhong H (2011) Dendritic cells combining with cytokine-induced killer cells synergize chemotherapy in patients with late-stage non-small cell lung cancer. Cancer Immunol Immunother 60:1497–1502

    Article  CAS  PubMed  Google Scholar 

  • Zhu H, Yang X, Li J, Ren Y, Zhang T, Zhang C, Zhang J, Pang Y (2014) Immune response, safety, and survival and quality of life outcomes for advanced colorectal cancer patients treated with dendritic cell vaccine and cytokine-induced killer cell therapy. Biomed Res Int 2014(2014):603871–603871

    Google Scholar 

  • Zonderman AB, Costa PT, McCrae RR (1989) Depression as a risk for cancer morbidity and mortality in a nationally representative sample. JAMA 262:1191–1195

    Article  CAS  PubMed  Google Scholar 

  • Zustovich F, Cartei G, Pastorelli D, Nicoletto O, Gottardo F, de Zorzi L et al (2007) A phase II study of gemcitabine at fixed infusion rate of 10 mg/m2/min with or without immunotherapy in advanced renal cancer. Anticancer Res 27:4461–4464

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Research Center for Immunodeficiencies, Children’s Medical Center, Tehran University of Medical Sciences, Dr. Qarib St, Keshavarz Blvd, Tehran, 14194, Iran

    Amene Saghazadeh & Nima Rezaei

  2. Systematic Review and Meta-Analysis Expert Group (SRMEG), Universal Scientific Education and Research Network (USERN), Tehran, Iran

    Amene Saghazadeh

  3. Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

    Nima Rezaei

  4. Cancer Immunology Project (CIP), Universal Scientific Education and Research Network (USERN), Tehran, Iran

    Nima Rezaei

Authors
  1. Amene Saghazadeh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nima Rezaei
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nima Rezaei .

Editor information

Editors and Affiliations

  1. Department of Medical Genetics, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

    Parvin Mehdipour

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this chapter

Cite this chapter

Saghazadeh, A., Rezaei, N. (2017). Cancer Immunotherapy: Friend or Foe of Mental Health?. In: Mehdipour, P. (eds) Cancer Genetics and Psychotherapy. Springer, Cham. https://doi.org/10.1007/978-3-319-64550-6_16

Download citation

Publish with us

Policies and ethics

Search

Navigation